Aoti

Aoti ROIC

The Return on Invested Capital (ROIC) of Aoti (AOTI.L) as of Nov 22, 2026 is 6.70 %. In the previous year, Return on Invested Capital (ROIC) was -6.66 % — a change of -200.62% (higher).

ROIC

6.70 %

YoY

-200.62%

Last updated:

Return on Invested Capital (ROIC) of Aoti is 2025 6.70 % . Return on Invested Capital (ROIC) of Aoti was 2024 -6.66 % . It decreases by -200.62% higher compared to the previous year.

The Aoti ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2021
113.06 USD
Jan 1, 2022
-21.29 USD
Jan 1, 2023
-127.11 USD
Jan 1, 2024
-6.66 USD
Jan 1, 2025
6.70 USD
The Aoti ROIC history
YEARROICYoY
6.70 %-200.62%
-6.66 %-94.76%
-127.11 %+496.96%
-21.29 %-118.83%
113.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aoti Stock analysis

What does Aoti do? Aoti Inc generates revenue through its wound care technology products, primarily TWO2 therapy and NEXA Negative Pressure Wound Therapy (NPWT). The company's TWO2 therapy solutions include TWO2 Extremity Chamber and TWO2 Multi-Patch, designed for patient-administered treatment of chronic wounds. NEXA NPWT System is a disposable, multi-week solution for wound care, targeting healthcare providers who manage chronic wound cases. Aoti focuses on enhancing access to care and improving clinical outcomes for patients with chronic conditions, leveraging robust clinical evidence to support its products' safety and efficacy. Healthcare providers and institutions purchasing TWO2 and NEXA systems form the primary customer segment, driven by the need for clinically proven wound care solutions. The company's products are positioned to address chronic wound management globally, with emphasis on patient quality of life and health equity. Aoti's business model centers on delivering evidence-based therapies that improve patient outcomes while meeting healthcare systems' demands for effective, efficient care delivery. The company's revenue streams are derived from direct sales of TWO2 and NEXA systems to healthcare facilities and practitioners. Product offerings are structured to support both acute and chronic wound care needs, with TWO2 being a multi-modality patient-administered therapy and NEXA providing a flexible, disposable NPWT system. Aoti's focus on clinical evidence ensures its solutions align with healthcare providers' requirements for safety and efficacy in wound treatment. Aoti is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aoti stock

Return on Invested Capital (ROIC) of Aoti is 6.70 % in 2025.

Return on Invested Capital (ROIC) of Aoti changed from -6.66 % to 6.70 %, representing a -200.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Aoti since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Aoti with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Aoti

All Key Metrics — Aoti